{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:16:20Z","timestamp":1760955380254},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T00:00:00Z","timestamp":1351555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1475-2840-11-134","type":"journal-article","created":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T13:17:35Z","timestamp":1351689455000},"source":"Crossref","is-referenced-by-count":25,"title":["Olmesartan\/amlodipine\/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study"],"prefix":"10.1186","volume":"11","author":[{"given":"Dean J","family":"Kereiakes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G","family":"Chrysant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Joseph L","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Thomas","family":"Littlejohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Melino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinilde","family":"Heyrman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,30]]},"reference":[{"key":"579_CR1","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/archinte.1993.00410050036006","volume":"153","author":"J Stamler","year":"1993","unstructured":"Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993, 153: 598-615. 10.1001\/archinte.1993.00410050036006.","journal-title":"Arch Intern Med"},{"key":"579_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jash.2010.03.005","volume":"4","author":"GL Bakris","year":"2010","unstructured":"Bakris GL, Sowers JR, Glies TD, Black HR, Izzo JL, Materson BJ, et al: Treatment of hypertension in patients with diabetes\u2013an update. J Am Soc Hypertens. 2010, 4: 62-67. 10.1016\/j.jash.2010.03.005.","journal-title":"J Am Soc Hypertens"},{"issue":"2 Suppl 2","key":"579_CR3","first-page":"S12","volume":"49","author":"National Kidney Foundation","year":"2007","unstructured":"National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007, 49 (2 Suppl 2): S12-S154.","journal-title":"Am J Kidney Dis"},{"key":"579_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1161\/HYPERTENSIONAHA.111.175463","volume":"58","author":"ML Bertoia","year":"2011","unstructured":"Bertoia ML, Waring ME, Gupta PS, Roberts MB, Eaton CB: Implications of new hypertension guidelines in the United States. Hypertension. 2011, 58: 361-366. 10.1161\/HYPERTENSIONAHA.111.175463.","journal-title":"Hypertension"},{"key":"579_CR5","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003, 289: 2560-2572. 10.1001\/jama.289.19.2560.","journal-title":"JAMA"},{"key":"579_CR6","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1161\/CIRCULATIONAHA.107.183885","volume":"115","author":"C Rosendorff","year":"2007","unstructured":"Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, et al: Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007, 115: 2761-2788. 10.1161\/CIRCULATIONAHA.107.183885.","journal-title":"Circulation"},{"key":"579_CR7","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1001\/archinte.167.22.2431","volume":"167","author":"ND Wong","year":"2007","unstructured":"Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS: Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003\u20132004. Arch Intern Med. 2007, 167: 2431-2436. 10.1001\/archinte.167.22.2431.","journal-title":"Arch Intern Med"},{"key":"579_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","volume":"123","author":"PA Heidenreich","year":"2011","unstructured":"Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al: Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011, 123: 933-944. 10.1161\/CIR.0b013e31820a55f5.","journal-title":"Circulation"},{"key":"579_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1751-7176.2008.08172.x","volume":"10","author":"RE Schmieder","year":"2008","unstructured":"Schmieder RE, Ruilope LM: Blood pressure control in patients with comorbidities. J Clin Hypertens (Greenwich). 2008, 10: 624-631. 10.1111\/j.1751-7176.2008.08172.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"579_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345: 851-860. 10.1056\/NEJMoa011303.","journal-title":"N Engl J Med"},{"key":"579_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345: 861-869. 10.1056\/NEJMoa011161.","journal-title":"N Engl J Med"},{"key":"579_CR12","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993, 329: 1456-1462. 10.1056\/NEJM199311113292004.","journal-title":"N Engl J Med"},{"key":"579_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1751-7176.2010.00360.x","volume":"12","author":"AH Gradman","year":"2010","unstructured":"Gradman AH: Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010, 12: 869-878. 10.1111\/j.1751-7176.2010.00360.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"579_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jash.2010.02.005","volume":"4","author":"AH Gradman","year":"2010","unstructured":"Gradman AH, Basile JN, Carter BL, Bakris GL: Combination therapy in hypertension. J Am Soc Hypertens. 2010, 4: 42-50. 10.1016\/j.jash.2010.02.005.","journal-title":"J Am Soc Hypertens"},{"key":"579_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.clinthera.2007.05.010","volume":"29","author":"V Fung","year":"2007","unstructured":"Fung V, Huang J, Brand R, Newhouse JP, Hsu J: Hypertension treatment in a Medicare population: adherence and systolic blood pressure control. Clin Ther. 2007, 29: 972-984. 10.1016\/j.clinthera.2007.05.010.","journal-title":"Clin Ther"},{"key":"579_CR16","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.clinthera.2010.07.008","volume":"32","author":"S Oparil","year":"2010","unstructured":"Oparil S, Melino M, Lee J, Fernandez V, Heyrman R: Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010, 32: 1252-1269. 10.1016\/j.clinthera.2010.07.008.","journal-title":"Clin Ther"},{"key":"579_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1751-7176.2011.00588.x","volume":"14","author":"DJ Kereiakes","year":"2012","unstructured":"Kereiakes DJ, Chrysant SG, Izzo JL, Littlejohn TI, Oparil S, Melino M, et al: Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide for hypertension. J Clin Hypertens. 2012, 14: 149-157. 10.1111\/j.1751-7176.2011.00588.x.","journal-title":"J Clin Hypertens"},{"key":"579_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1751-7176.2011.00437.x","volume":"13","author":"MR Weir","year":"2011","unstructured":"Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJI, Graff A, Shojaee A, et al: A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil \u00b1 hydrochlorothiazide. J Clin Hypertens (Greenwich). 2011, 13: 404-412. 10.1111\/j.1751-7176.2011.00437.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"579_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/BF03261832","volume":"12","author":"SG Chrysant","year":"2012","unstructured":"Chrysant SG: Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in blacks and non-blacks with hypertension: a subgroup analysis of the TRINITY study. Am J Cardiovasc Drugs. 2012, 12: 233-243.","journal-title":"Am J Cardiovasc Drugs"},{"key":"579_CR20","volume-title":"Ethical principles for medical research involving human subjects","author":"World Medical Association Declaration of Helsink","year":"2010","unstructured":"World Medical Association Declaration of Helsink: Ethical principles for medical research involving human subjects. 2010, World Medical Association, \n                    http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/17c.pdf\n                    \n                  ."},{"key":"579_CR21","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008, 359: 2417-2428. 10.1056\/NEJMoa0806182.","journal-title":"N Engl J Med"},{"key":"579_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"WC Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002, 4: 393-404. 10.1111\/j.1524-6175.2002.02045.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"579_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ahj.2008.02.023","volume":"156","author":"S Bangalore","year":"2008","unstructured":"Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, et al: Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J. 2008, 156: 241-247. 10.1016\/j.ahj.2008.02.023.","journal-title":"Am Heart J"},{"key":"579_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1185\/030079906X162854","volume":"23","author":"RB Devereux","year":"2007","unstructured":"Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, et al: Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin. 2007, 23: 259-270. 10.1185\/030079906X162854.","journal-title":"Curr Med Res Opin"},{"key":"579_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1753944709334947","volume":"3","author":"F Elijovich","year":"2009","unstructured":"Elijovich F, Laffer C: A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis. 2009, 3: 231-240. 10.1177\/1753944709334947.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"579_CR26","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1185\/03007990802319364","volume":"24","author":"DI Brixner","year":"2008","unstructured":"Brixner DI, Jackson KC, Sheng X, Nelson RE, Keskinaslan A: Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free- and fixed-dose combinations. Curr Med Res Opin. 2008, 24: 2597-2607. 10.1185\/03007990802319364.","journal-title":"Curr Med Res Opin"},{"key":"579_CR27","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.clinthera.2008.08.010","volume":"30","author":"KC Jackson","year":"2008","unstructured":"Jackson KC, Sheng X, Nelson RE, Keskinaslan A, Brixner DI: Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther. 2008, 30: 1558-1563. 10.1016\/j.clinthera.2008.08.010.","journal-title":"Clin Ther"},{"key":"579_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1753944709356012","volume":"4","author":"J Basile","year":"2010","unstructured":"Basile J, Neutel J: Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther Adv Cardiovasc Dis. 2010, 4: 119-127. 10.1177\/1753944709356012.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"579_CR29","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1517\/14656560902980210","volume":"10","author":"DA Calhoun","year":"2009","unstructured":"Calhoun DA: Use of single-pill combination therapy in the evolving paradigm of hypertension management. Expert Opin Pharmacother. 2009, 10: 1869-1874. 10.1517\/14656560902980210.","journal-title":"Expert Opin Pharmacother"},{"key":"579_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/00044011-200828110-00005","volume":"28","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG: Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig. 2008, 28: 713-734. 10.2165\/00044011-200828110-00005.","journal-title":"Clin Drug Investig"},{"key":"579_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","volume":"120","author":"S Bangalore","year":"2007","unstructured":"Bangalore S, Kamalakkannan G, Parkar S, Messerli FH: Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007, 120: 713-719. 10.1016\/j.amjmed.2006.08.033.","journal-title":"Am J Med"},{"key":"579_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","volume":"55","author":"AK Gupta","year":"2010","unstructured":"Gupta AK, Arshad S, Poulter NR: Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010, 55: 399-407. 10.1161\/HYPERTENSIONAHA.109.139816.","journal-title":"Hypertension"},{"key":"579_CR33","first-page":"568","volume":"16","author":"DG Pittman","year":"2010","unstructured":"Pittman DG, Tao Z, Chen W, Stettin GD: Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010, 16: 568-576.","journal-title":"Am J Manag Care"},{"key":"579_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000321688","volume":"32","author":"KE Schmitt","year":"2010","unstructured":"Schmitt KE, Edie CF, Laflam P, Simbartl LA, Thakar CV: Adherence to antihypertensive agents and blood pressure control in chronic kidney disease. Am J Nephrol. 2010, 32: 541-548. 10.1159\/000321688.","journal-title":"Am J Nephrol"},{"key":"579_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009, 122: 290-300. 10.1016\/j.amjmed.2008.09.038.","journal-title":"Am J Med"},{"key":"579_CR36","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009, 338: b1665-10.1136\/bmj.b1665.","journal-title":"BMJ"},{"key":"579_CR37","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007, 25: 1105-1187. 10.1097\/HJH.0b013e3281fc975a.","journal-title":"J Hypertens"},{"key":"579_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1475-2840-11-32","volume":"11","author":"SG Mallat","year":"2012","unstructured":"Mallat SG: What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?. Cardiovasc Diabetol. 2012, 11: 32-10.1186\/1475-2840-11-32.","journal-title":"Cardiovasc Diabetol"},{"key":"579_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jacc.2011.05.002","volume":"58","author":"J Drozda Jr","year":"2011","unstructured":"Drozda J, Messer JV, Spertus J, Abramowitz B, Alexander K, Beam CT, et al: ACCF\/AHA\/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. J Am Coll Cardiol. 2011, 58: 316-336. 10.1016\/j.jacc.2011.05.002.","journal-title":"J Am Coll Cardiol"},{"key":"579_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","volume":"304","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al: Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010, 304: 61-68. 10.1001\/jama.2010.884.","journal-title":"JAMA"},{"key":"579_CR41","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, et al: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010, 362: 1575-1585.","journal-title":"N Engl J Med"},{"key":"579_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007, 370: 829-840. 10.1016\/S0140-6736(07)61303-8.","journal-title":"Lancet"},{"key":"579_CR43","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009, 27: 2121-2158. 10.1097\/HJH.0b013e328333146d.","journal-title":"J Hypertens"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2840-11-134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1475-2840-11-134\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2840-11-134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T18:19:23Z","timestamp":1581963563000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/1475-2840-11-134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,30]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1186\/1475-2840-11-134","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,30]]},"article-number":"134"}}